Shire plc / New River Pharmaceuticals Inc.

Attention-Deficit/Hyperactivity Disorder (ADHD)

Disease Overview

ADHD is a neurodevelopmental disorder marked by inattention, hyperactivity, and impulsivity affecting both children and adults, with the majority of pharmacologic treatment delivered via stimulant medications targeting dopamine and norepinephrine signaling. The category is large, chronic, and DEA Schedule II controlled, making abuse potential and patent protection central commercial levers.

Competitive Landscape

In 2007 the US ADHD stimulant market was led by Shire's Adderall XR (mixed amphetamine salts, $864M 2006 sales), Novartis/Janssen's Concerta (methylphenidate ER), Eli Lilly's Strattera (atomoxetine, the only non-stimulant), and Shire's Daytrana methylphenidate patch. Adderall XR faced patent expiry and authorized-generic exposure in 2009, threatening roughly half of Shire's revenue. Vyvanse (lisdexamfetamine dimesylate) was a New River-developed prodrug covalently binding dextroamphetamine to L-lysine, requiring GI enzymatic cleavage to release active drug, which slowed onset and reduced abuse liability vs. Adderall XR. Under the prior collaboration, Shire owed New River up to ~60% of Vyvanse profits. The $64/share, ~$2.6B all-cash deal announced February 20, 2007 - closed shortly after FDA approval February 23, 2007 - eliminated that economic split, secured the Adderall XR successor, and added New River's NRP290 abuse-resistant opioid program. Vyvanse went on to peak above $2B in annual revenue.